Table. Baseline Demographics.
| Variable | No. (%) | CHIP vs no CHIP P valuea | |||
|---|---|---|---|---|---|
| All (N = 10 061) | Genomic (n = 3923) | No CHIP (n = 3585) | CHIP (n = 338) | ||
| Age, mean (SD), y | 61.1 (10.0) | 61.9 (9.7) | 61.5 (9.6) | 66.3 (9.2) | <.001 |
| Female | 2587 (25.7) | 994 (25.3) | 898 (25.1) | 96 (28.4) | .19 |
| Male | 7474 (74.3) | 2929 (74.7) | 2687 (75.0) | 242 (71.6) | |
| Race | |||||
| Asian | 1163 (11.6) | 192 (4.9) | 179 (5.0) | 13 (3.9) | .30 |
| Black | 318 (3.2) | 131 (3.3) | 122 (3.4) | 9 (2.7) | |
| White | 8036 (79.9) | 3537 (90.2) | 3223 (89.9) | 314 (92.9) | |
| Otherb | 544 (5.4) | 63 (1.6) | 61 (1.7) | 2 (0.6) | |
| Current smoker | 2366 (23.5) | 1032 (26.3) | 954 (26.6) | 78 (23.1) | .17 |
| Diabetes at baseline | 4057 (40.3) | 1630 (41.6) | 1494 (41.7) | 136 (40.2) | .64 |
| Hypertension at baseline | 8008 (79.6) | 3187 (81.2) | 2896 (80.8) | 291 (86.1) | .02; .09c |
| Time since qualifying MI, mean (SD), y | 4.57 (5.37) | 5.33 (5.75) | 5.26 (5.70) | 6.0 (6.24) | .11 |
| Prior PCI | 6710 (66.7) | 2720 (69.4) | 2487 (69.4) | 233 (68.9) | .85 |
| Prior CABG | 1411 (14.0) | 678 (17.3) | 611 (17.1) | 67 (19.8) | .20 |
| History of heart failure | 2173 (21.6) | 761 (19.4) | 672 (18.7) | 89 (26.3) | .001; .02c |
| Statin use | 8891 (88.4) | 3447 (87.9) | 3155 (88.0) | 292 (86.4) | .38 |
| RAAS inhibitor use at baseline | 7992 (79.7) | 3140 (80.4) | 2873 (80.5) | 267 (79.2) | .57 |
| Prior anti-ischemic agent use | 9191 (91.4) | 3624 (92.4) | 3301 (92.1) | 323 (95.6) | .02 |
| Use of antithrombotic medication | 9747 (97.0) | 3822 (97.6) | 3491 (97.5) | 331 (97.9) | .85 |
| Total cholesterol, median (IQR), mg/dL | 160.0 (136.1-189.0) | 161.0 (138.0-189.5) | 161.3 (138.1-189.9) | 159.9 (135.0-186.4) | .25 |
| LDL cholesterol derived, median (IQR), mg/dL | 82.4 (63.4-107.1) | 83.5 (65.0-107.0) | 83.5 (65.4-107.1) | 83.9 (63.80-104.0) | .43 |
| eGFR, median (IQR), mL/min/1.73/m2 | 79.0 (64.0-93.0) | 78.0 (64.0-92.0) | 78.0 (65.0-93.0) | 72.0 (56.0-84.0) | <.001; .001c |
| hs-CRP, median (IQR), mg/dL | 4.20 (2.80-7.05) | 4.20 (2.80-6.90) | 4.20 (2.80-6.85) | 4.40 (2.95-7.10) | .47 |
| Interleukin 18, median (IQR), ng/Ld | 260 (201-340) | 262 (202-342) | 262 (203-342) | 256 (194-337) | .40 |
| Interleukin 6, median (IQR), ng/Le | 2.58 (1.78-4.10) | 2.55 (1.77-4.09) | 2.53 (1.77-4.03) | 2.97 (1.86-4.70) | .003 |
Abbreviations: CABG, coronary artery bypass surgery; CHIP, clonal hematopoiesis of indeterminate potential; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention; RAAS, renin-angiotensin-aldosterone system.
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259; hs-CRP to milligrams per liter, multiply by 10.
P values were calculated using Fisher exact test for categorical variables and Mann-Whitney test for continuous variables.
Other included Native American, Pacific Islander, other, or unknown.
P values adjusted for age and sex.
Number of patients analyzed for interleukin 18: all, n = 5071; genomic substudy, n = 3801; patients with CHIP, n = 323.
Number of patients analyzed for interleukin 6: all, n = 5058; genomic substudy, n = 3788; patients with CHIP, n = 322.